key: cord-0740561-mqvho63h
authors: Farrell, Ruth M.; Pierce, Madelyn; Collart, Christina; Craighead, Caitlin; Coleridge, Marissa; Chien, Edward K.; Perni, Uma; Frankel, Richard; Ranzini, Angela; Edmonds, Brownsyne Tucker; Rose, Susannah S.
title: The impact of the emergence of COVID‐19 on women's prenatal genetic testing decisions
date: 2021-03-05
journal: Prenat Diagn
DOI: 10.1002/pd.5902
sha: 6b7e2b739cf0fc701c1dbc9316fdbcab683eac43
doc_id: 740561
cord_uid: mqvho63h

OBJECTIVE: We conducted a study to examine the impact of COVID on patients' access and utilization of prenatal genetic screens and diagnostic tests at the onset of the COVID‐19 pandemic in the United States. METHODS: We conducted telephone interviews with 40 patients to examine how the pandemic affected prenatal genetic screening and diagnostic testing decisions during the initial months of the pandemic in the United States. An interview guide queried experiences with the ability to access information about prenatal genetic testing options and to utilize the tests when desired. Audio recordings were transcribed and coded using NVivo 12. Analysis was conducted using Grounded Theory. RESULTS: The pandemic did not alter most participants' decisions to undergo prenatal genetic testing. Yet, it did impact how participants viewed the risks and benefits of testing and timing of testing. There was heightened anxiety among those who underwent testing, stemming from the risk of viral exposure and the fear of being alone if pregnancy loss or fetal abnormality was identified at the time of an ultrasound‐based procedure. CONCLUSION: The pandemic may impact patients' access and utilization of prenatal genetic tests. More research is needed to determine how best to meet pregnant patients' decision‐making needs during this time.

Prenatal genetic screening tests and diagnostic tests (collectively referred to as prenatal genetic tests in this manuscript) are a core component of delivering high-quality, evidence-based prenatal care. [1] [2] [3] [4] This includes prenatal genetic screening tests performed by analyzing maternal serum or ultrasound and diagnostic tests performed by amniocentesis or chorionic villus sampling. 2 Prenatal genetic tests are highly time-sensitive as delays can have significant implications for obstetric outcomes. 5, 6 Thus, it is critical to understand if and how the pandemic may affect patients' ability to access prenatal genetic tests in an informed and timely fashion during this time.

It is currently unknown if and how the COVID-19 pandemic may affect pregnant women's decision-making about the use of prenatal genetic tests. A rapid and massive response to the virus took place across healthcare systems, with telehealth implementation as a core component of these changes to mitigate the risk of viral exposure among patients, healthcare providers, and communities. 7 This approach helped maintain prenatal care delivery while avoiding the possible risks associated with an in-person visit, a strategy particularly relevant to pregnant patients because of the known and unknown implications of COVID-19 for maternal and neonatal outcomes. 7 Yet, in-person visits are required for those patients who elect for prenatal genetic testing. The decision to proceed with testing requires the patient to have a blood draw or ultrasoundbased procedure. These processes entail presenting to a healthcare facility and breaking social distancing to be in close proximity to a clinician performing the procedure. How pregnant patients will consider the risks of COVID exposure in their decisions about if to undergo testing, what kind of test to use, and when to have testing performed are unknown.

Given the potential effects of COVID-19 on maternal and neonatal outcomes and the importance of prenatal genetic testing for the delivery of high-quality prenatal care, we conducted a study to assess the pandemic's onset on women's decision-making for prenatal genetic testing. This time frame is significant as it represents the rapid influx of new information, policies, and procedures about the virus and the pandemic. These data are critical to developing COVID-19 strategies for the delivery of prenatal care that reflect pregnant patients' decision-making needs as they navigate the fast-paced and novel changes associated with the pandemic.

Board of the Cleveland Clinic Healthcare System. Participants were 18 years of age or older, English speaking, received outpatient obstetric care through Cleveland Clinic Healthcare System, and had a viable intrauterine pregnancy. We recruited pregnant women at outpatient centers within Cleveland Clinic Healthcare System between May and July 2020. This is a major healthcare system in Cleveland, Ohio that has over 10,000 deliveries a year. We selected this timeframe as it reflected the onset and first major wave of the pandemic in United States and Ohio ( Figure 1 ). For reference, there were an average of 564 cases per day at the start of data collection in May, which doubled to roughly 1270 cases per day at the end of data collection in July. 8 During this time, telehealth was instituted across the healthcare system and, while encouraged, not required.

Participants were contacted by means of a recruitment letter.

The recruitment letter indicated if the women were interested in sharing their knowledge and opinions of decision-making surrounding prenatal testing in light of the COVID-19 pandemic, to contact the research team for participation. Recruitment was structured to seek input from two groups of women who represent patients at different significant time points in pregnancy. One group included women in the first trimester of pregnancy to capture prenatal care needs, preferences, and experiences at the onset of the pregnancy and prenatal care delivery (Group 1). A second group included women in the second trimester, who had already considered or undergone prenatal genetic screening or diagnostic testing at the time of the interview (Group 2). Recruitment was continued until thematic saturation was reached.

After an informed consent process, each participant participated in a telephone interview to maintain consistency with the healthcare system's recommendations for social distancing and patient contact for research purposes at the onset of the pandemic. Interviews were conducted by a member of the research team using a structured interview guide containing questions about knowledge and perception of the COVID-19 pandemic and the impact on their prenatal care (Appendix S1). Items specific to prenatal genetic testing inquired about participants' baseline perceptions of the benefits and limitations of screens and diagnostic tests and how they would weigh these risks and benefits against the potential risks of COVID-19 exposure by presenting for testing procedures. This guide was developed in conjunction with content experts in obstetrics, clinical genetics, medical decision-making, patient experience, and maternal-fetal medicine. With the participants' permission, the interviews were audio recorded for analysis.

Analysis was approached as an iterative and progressive process of data immersion, coding, memoing, and theme identification, an inductive process consistent with Grounded Theory. 9,10 We identified content domains and categories in transcripts to create a coding tree used to organize the data. A companion codebook was created to serve as a reference for the analysis. The transcripts were coded by two members of the team (R. Farrell and M. Pierce) using NVivo (version 12). The research team held weekly meetings to identify themes by reviewing data, coding, and analytic memos to resolve any coding disagreements. Themes identified were contextualized with information about the trimester of pregnancy, gravity/parity, and previous pregnancies.

We contacted 115 (first trimester) and 139 (second trimester) patients for study participation. We recruited a total of 40 pregnant women to take part in the study: 20 in their first trimester (Group 1) and 20 in their second trimester (Group 2; Table 1 ). The majority (36) had already undergone prenatal aneuploidy screening or intended to undergo prenatal aneuploidy screening during the pregnancy. None Table 2 .

The decision to proceed with prenatal genetic testing during the pandemic.

Overall, we found that the pandemic did not significantly alter most patients' choice to undergo or defer prenatal genetic testing.

Yet, it did impact how all participants considered the benefits and risks of testing and the emotional reactions they experienced in the process. Participants were aware of the possible risks of SARS-CoV-2 exposure by presenting for testing and the uncertainties of COVID-19 for pregnant women and newborns. These were factors they weighted in their decision-making process. However, the concern for COVID-19 did not often take priority in decisions to seek testing. As one participant stated, "The reward greatly outweighed the risk" (G2-10).

Most participants viewed the benefits of learning about the fetus through prenatal genetic testing as greater than the risk of potential exposure to the virus in the process of undergoing testing. The reasons for those benefits fell into two broad categories. For one group, the benefits of prenatal genetic testing remained unchanged despite the pandemic. These women sought information so that they could make the decisions they felt were most appropriate for the future child and their family. As described by this participant:

"So, it 

Yet, for some, the pandemic presented too much of a threat. For these participants, the decision for testing was either delayed or deferred, even when it may have been seen as a value before the pandemic. As There was also the recognition that delaying testing may not be an effective strategy to avoid the threats posed by the pandemic. As described by this participant, "I felt like this pandemic was going to be unpredictable and was going to be a while for things to settle down anyways. I thought that the pregnancy weeks would come a lot faster than the pandemic settling down" (G2-23).

Participants were cognizant of the potential for pandemicrelated delays to access healthcare, including accessing both the personnel and the healthcare facilities required for testing. One concern participants had was that, if they did not proceed with prenatal genetic testing when it was initially offered, they might not be able to access it later due to unanticipated COVID- 19 

Participants who sought prenatal genetic testing despite the con- G1-03) . However, many elected to proceed with their choice despite the potential concern and distress resulting from presenting for testing.

For some participants, their concern was heightened due to the location where they had to present for testing. One concern pertained to being in a healthcare facility where many other patients were seeking care and the choices those patients may make concerning infection-prevention approaches (e.g., social distancing, wearing masks). As described by this participant, "I'm also not really thrilled about going to the lab just because I know that those are generally busier places and it's harder to control the number of people" (G1-16).

There was also concern about presenting for testing in a hospital Participants discussed another significant concern: fear and anxiety of being alone during the testing process. As a result of visitor restriction policies, many participants underwent ultrasound-based screening and diagnostic testing procedures without a partner or support person. This was a concern for women who wanted to share the experience of seeing the fetus with a partner. Yet, for many, the Our study sheds light on two major factors that may interfere with patient's ability to make informed decisions about their prenatal genetic testing options and access these tests during the pandemic.

First, the study findings highlight the increased complexity of the prenatal genetic testing decision-making process during the pandemic. We found that during the pandemic, participants expanded the number of risks and benefits they weighed in the decision-making process, adding to the existing set of risks and limitations already associated with prenatal genetic testing. For instance, participants incorporated the possible risks of exposure to SARS-CoV-2 by presenting for testing to the decision-making process. The risk of COVID did not represent one single concern.

Instead, COVID presented a series of additional risks and implications to consider. This included not just the risks of exposure for themselves and the pregnancy but, more significantly, the risks, implications, sense of culpability, and feelings of regret if their children and other adults in the family became ill as a result of the decision to present to the healthcare facility for testing. These risks, in addition to those associated with prenatal genetic testing, presented an array of different implications for the pregnancy and family.

The decision-making process also entailed an expanded view of the potential benefits of prenatal genetic testing. Participants in this study sought prenatal genetic testing as a source of reassurance during the pregnancy, a finding consistent with other studies. [13] [14] [15] Yet, for participants in this study, there was a greater urgency for reassurance in response to the numerous medical, personal, financial, and social uncertainties caused by the pandemic, something that some felt could be gained from prenatal genetic testing. In fact, some were interested in gaining as much genetic information about the fetus as possible in an effort to obtain the degree of reassurance they felt they needed during this time. This reassurance was seen as an additional benefit that they incorporated into decision-making. For those who underwent testing, this consideration provided further justification for their decision. For others, this perceived benefit led to the decision for testing when they would not have considered it prior to the pandemic. Notably, there was no discussion of the uncertainties that can come with prenatal genetic testing. Yet, this is an important consideration in the decision-making process, particularly in the posttest setting when potentially unexpected or uninterpretable results may be received. 16, 17 This finding raises the question of how we can help patients balance the reassurance they seek during the pandemic with a realistic view of the questions that may not be answered by prenatal genetic tests or may arise in the testing process.

Key drivers in the decision-making process were notions of responsibility and obligation to make choices about prenatal genetic testing during the pandemic that would best benefit a newborn and family. Other authors have observed this decision-making factor, a concept often referred to as the "Good Mother" which describes a self and society-imposed sense of obligations for pregnant women to take on or avoid risks for the benefit of the child. 18, 19 Our study highlights that this factor and the pressure to "make the right decision" was further amplified during the pandemic when patients considered the risks and uncertainties that may come with the decision to utilize prenatal genetic tests, defer them to a later time in the pandemic, or decline testing altogether during the current pregnancy.

A second major factor to impact the decision-making process was anxiety. It is recognized that increased levels of anxiety and distress can negatively affect the decision-making process, presenting challenges for obtaining medical information and processing it in a way, that is, consistent with one's values and preferences. 20, 21 Studies have shown that pregnant patients frequently experience anxiety and uncertainty during prenatal genetic testing. 13, 22, 23 Yet, the COVID-19 pandemic has provoked a series of other concerns for pregnant women considering prenatal genetic testing, sources of anxiety that have not been fully identified with past infectious disease threats. 24, 25 As described above, the pressure to make "the right decision" weighed heavily on participants. In addition, there was concern about the ability to access the healthcare system and tests in a timely manner due to both disruptions in healthcare provision and the feeling of trust and safety in the clinical environment. As the COVID-19 pandemic has led to unprecedented changes in healthcare delivery, it is not possible to compare these concerns with pregnant patients' experiences considering other infectious threats. Yet, the sequelae of delays and barriers to prenatal care and prenatal genetic tests are well-documented apart from the pandemic. 5 Such issues are particularly significant among those who already face barriers to early prenatal care, 6 raising the concern of further exacerbation of inequities and healthcare disparities resulting from COVID-19. 26, 27 Given these concerns, it is critical to ensure that preventable delays to patients' access prenatal genetic test access are avoided.

Another source of anxiety was noted: the fear of being alone and without their partner or support person when a fetal abnormality or pregnancy loss was diagnosed. Some participants found themselves undergoing an ultrasound-based procedure without their partner as a result of visitor restriction policies. For many, this was an unexpected feeling, something that they did not realize until the testing procedure was taking place. This is significant for several reasons.

Studies show that many pregnant women elect to include a partner or other support person in the prenatal genetic testing process and several other aspects of prenatal care, a finding also noted among our participants. [28] [29] [30] [31] 

Our study sheds light on the impact of COVID-19 on patients' decision-making needs and preferences during the uncertainty of the pandemic. These findings demonstrate the need for effective tools and strategies to ensure that patients' informed access to prenatal genetic tests is not impaired by the pandemic. This is significant as such barriers that emerge during the time period of the pandemic may have a long-term indelible impact on women, their families, and their future family building decisions. As a next step, it is critical to further understand the nature, extent, and impact of COVID-19 on women's ability to access prenatal genetic tests in a timely and informed manner, with implications not just for patient care during the current pandemic and future public health events that cause major disruptions in healthcare delivery.

We would like to acknowledge Lin Mei for assisting in the recruitment of study participants. This study was funded by a grant from the Human Genome Research Institute (R01HG010092).

Susannah Rose received speaking honorariums and travel funding within the past three years from Siemens Healthineers, Panagora

Pharma, Healthcare Information and Management Systems Society, Inc. (HIMSS). Next Generation Patient Experience (NGPX), and healthcare systems in Sweden and Saudi Arabia on topics related to public health, bioethics, and health policy. Other authors declare that they have no conflict of interests to declare:

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

Ruth M. Farrell https://orcid.org/0000-0002-8258-8842

Caitlin Craighead https://orcid.org/0000-0003-1889-0200

Genetic screening and testing in an episode-based payment models preserving patient autonomy

163: screening for fetal aneuploidy

Noninvasive prenatal screening for fetal aneuploidy, 2016 update: a position statement of the American College of Medical Genetics and Genomics

Patient-centered obstetric care in the age of cell-free fetal DNA prenatal screening

Maximizing the benefits and minimizing the risks associated with prenatal genetic testing

Impact of early diagnosis and noninvasive prenatal testing (NIPT): knowledge, attitudes, and experiences of parents of children with sex chromosome aneuploidies (SCAs)

Conversion and optimization of telehealth in obstetric care during the COVID-19 pandemic

Trends in number of COVID-19 cases and deaths in the US reported to CDC by State/Territory; 2020

Basics of Qualitative Research: Techniques and Procedures for Developing Grounded Theory

Techniques to identify themes

Decision aid tools to support women's decision making in pregnancy and birth: a systematic review and meta-analysis

Computerized prenatal genetic testing decision-assisting tool: a randomized controlled trial

Women's experience with non-invasive prenatal testing and emotional wellbeing and satisfaction after test-results

The Genetic Construction of Prenatal Testing in Women and Prenatal Testing: Facing the Challenges of Genetic Technology

Noninvasive prenatal whole genome sequencing: pregnant women's views and preferences

Women's experiences receiving abnormal prenatal chromosomal microarray testing results

Integration of microarray technology into prenatal diagnosis: counselling issues generated during the NICHD clinical trial

Being a "good mother

Being a "good mother": managing breastfeeding and merging identities

Anxiety and decision-making

Predicting decisional conflict: anxiety and depression in shared decision making

onset and course of anxiety disorders during pregnancy: a systemic review and metaanalysis

Anxiety disorders in pregnancy

Attitudes about the 2009 H1N1 influenza pandemic among pregnant Japanese women and the use of the Japanese municipality as a source of information

Psychological impact of infectious disease outbreaks on pregnant women: rapid evidence review

Exploring the social determinants of racial/ethnic disparities in prenatal care utilization and maternal outcome

The role of public health in COVID-19 emergency response efforts from a rural health perspective

Playing second fiddle is okay-Swedish fathers' experiences of prenatal care

The effects of father involvement during pregnancy on receipt of prenatal care and maternal smoking

Active husband involvement during pregnancy: a grounded theory

Balancing needs and autonomy: the involvement of pregnant women's partners in decisions about cfDNA

An integrative review of fathers' experiences during pregnancy and childbirth

Impact of COVID-19 on the perinatal period through a biopsychosocial systemic framework

To suffer alone: hospital visitation policies during COVID-19

Aetna Will Cover Noninvasive Prenatal Testing for All Pregnancies

COVID-19: Aetna Expands NIPT Coverage for Young Pregnant Women. Bloomberg, 2020

Serum and Urine Marker Screening for Fetal Aneuploidy. Aetna

Uptrend in distress and psychiatric symptomatology in pregnant women during the coronavirus disease 2019 pandemic

The psychological experience of obstetric patients and health care workers after implementation of universal SARS-CoV-2 testing

Risk factors and course patterns of anxiety and depressive disorders during pregnancy and after delivery: a prospective-longitudinal study

The impact of the emergence of COVID-19 on women's prenatal genetic testing decisions